The potential of amifostine: From cytoprotectant to therapeutic agent

Haematologica

Volumn 84, Issue 11, 1999, Pages 1035-1042

  Santini, Valeria ^b   Giles, Francis J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Policlinico di Careggi   (Italy)

Author keywords

Amifostine; Chemotherapy; Cytoprotection; Myelodysplastic syndromes; Radiation

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; OXYGEN RADICAL;

CARDIOTOXICITY; CELL PROTECTION; CHEMOTHERAPY; DRUG ACTIVITY; HUMAN; HYPOTENSION; LUNG TOXICITY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; REVIEW; VOMITING;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; NEUTROPENIA; RADIATION-PROTECTIVE AGENTS; THROMBOCYTOPENIA;

EID: 0032734957     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Schuchter LM. Current role of protective agents in cancer treatment. Oncology 1997; 11:505-16.
2. Trotti A. Toxicity antagonists in cancer therapy. Curr Opin Oncol 1997; 9:569-78.
3. Griggs JJ. Reducing the toxicity of anticancer therapy: new strategies. Leuk Res 1998; 22:S27-33.
4. Capizzi RL. Amifostine: the preclinical basis for broadspectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996; 23(Suppl 8):2-17.
5. McCauley DL Amifostine: a novel cytoprotective agent. Cancer Pract 1997; 5:189-91.
6. Foster-Nora JA, Siden R. Amifostine for protection from antineoplastic drug toxicity. Am J Health-Syst Pharm 1997; 54:787-800.
7. Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42:4330-1.
8. Tannehill SP, Mehta MP. Amifostine and radiation therapy: past, present, and future. Semin Oncol 1996; 23(Suppl 8):69-77.
9. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine protects primitive hematopoiecic progenitors against chemotherapy cytotoxicity. Semin Oncol 1996; 23(Suppl8):58-63.
10. Dorr RT. Cytoprotective agents for anthracyclines. Semin Oncol 1996; 23(Suppl 8):23-34.
11. van der Vijgh WJF, Korst AEC. Amifostine (Ethyol®): pharmacokinetic and pharmacodynamic effects in vivo. Eur J Cancer 1996; 32A:S26-30.
12. Shaw LM, Glover D, Turrisi A, et al. Pharmacokinetics of WR-2721. Pharmacol Ther 1988; 39:195-201.
13. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward JF. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985; 47:23-7.
14. Fleckenstein L, Swynnerton NF, Ludden TM, Mangold DJ. Bioavailability and newer methods of delivery of phosphorothioate radioprotectors. Pharmacol Ther 1988; 39:203-12.
15. Shaw LM, Turrisi AT, Glover DJ, et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 1986; 12:1501-4.
16. Korst AEC, Gall HE, Vermorken JB, van der Vijgh WJF. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Cancer Chemother Pharmacol 1996; 39:162-6.
17. Utley JF, Seaver N, Newton GL, Fahey RC. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 1984; 10:1525-8.
18. Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Semin Oncol 1996; 23(Suppl 8):18-22.
19. Treskes M, Nijtmans LG, Fichtinger-Schepman AM, van der Vijgh WJ. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNAadducts in vitro in comparison to the effects of thiosulphate and diethyl-dithiocarbamate. Biochem Pharmacol 1992; 43: 1013-9.
20. Treskes M, Holwerda U, Nijtmans LG, Pinedo HM, van der Vijgh WJ. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278. Cancer Chemother Pharmacol 1992; 29:467-70.
21. Alberts DS, Speicher LA, Krutzsch M, et al. WR-1065, the active metabolite of amifostine (Ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Eur J Cancer 1996; 32A(Suppl 4): S17-20.
22. Kemp G, Rose P, Lurain J, et al. Amifostine pretreat-ment for protection against cyclophosphamideinduced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101-12.
23. Dunn TA, Schmoll H-J, Grunwald V, Bokemeyer C, Casper J. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model oftesticular cancer. Anticancer Drugs 1996; 7:795-9.
24. Aviles A, Diaz-Maqueo JC, Talavera A, Garcia EL, Guzman R, Nambo MJ. Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. Eur J Cancer 1997; 33:1323-5.
25. Paine GD, Taylor CW, Lopez MHA, Johnson CS, Capizzi RL. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Semin Oncol 1996; 23(Suppl 8):35-9.
26. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980; 40:1519-24.
27. Budd GT. Amifostine and chemotherapy-related thrombocytopenia. Semin Oncol 1996; 23(Suppl 8): 49-52.
28. Yau JC, Neidhart JA, Triozzi P, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Am J Hemato 1996;51:289-95.
29. Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macro-phage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993; 82:2329-39.
30. Peters GJ, van der Vijgh WJF. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur J Cancer 1995; 31A(Suppl 1):S1-7.
31. Wasserman TH, Phillips TL, Ross G, Kane LJ. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. Cancer Clin Trials 1981; 4:3-6.
32. Treskes M, Boven E, van de Loosdrecht AA, et al. Effects of the modulating agent WR2721 on myelotoxicityand antitumour activity in carboplatin-treated mice. Eur J Cancer 1994; 30A: 183-7.
33. Green D, Bensely D, Schein P. Preclinical evaluation of WR-151327: an orally active chemotherapy protector. Cancer Res 1994; 54:738-41.
34. van Laar JA, van der Wilt CL, Treskes M, van der Vijgh WJF, Peters GJ. Effect ofWR-2721 on the toxicity and antitumor activity of the combination ofcarboplatin and 5-fluorouracil. Cancer Chemother Pharmacol 1992; 31:97-102.
35. Yuhas JM, Spellman JM, Jordan SW, Pardini MC, Afzal SN, Culo F. Treatment of tumors with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. BrJ Cancer 1980; 42:574-85.
36. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980; 64:57-64.
37. Allalunis-Turner P, Siemann DW. Modification of cyclophosphamide-induced pulmonary toxicity in normal mice. NCI Monog 1988; 6:51-8.
38. Hunter NR, Guttenberger R, Milas L. Modification of radiation-induced carcinogenesis in mice by misonidazole and WR-2721. Int J Radiat Oncol Biol Phys 1992; 22:795-8.
39. Geng L, Hanson WR, Malkinson FD. Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation. Int J Radiat Oncol Biol 1992, 61:533-7.
40. Millar JL, McElwain TJ, Clutterbuck RD, Wist EA. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721). Am J Clin Oncol 1982; 5: 321-8.
41. Kligerman MM, Glover DJ, Turrisi AT, et al. Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 1984; 10:1773-6.
42. Kligerman MM, Turrisi AT, Urtasun RC, et al. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1988; 14:1119-22.
43. Click JH, Glover D, Weiler C, Norfoeet L, Yuhas J, Kligerman MM. Phase I controlled trials of WR-2721 and cyclophosphamide. Int J Radiat Oncol Biol Phys 1984; 10:1777-80.
44. Constine LS, Zagars G, Rubin P, Kligerman MM. Protection by WR-2721 of human bone marrow function following irradiation, Int J Radiat Oncol Biol Phys 1986; 12:1505-8.
45. Coia L, Krigel R, Ganks G, et al. A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies. Int J Radiat Oncol Biol Phys 1992; 22:791-4.
46. Wadler S, Goldberg G, Fields A, et al. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Semin Oncol 1996; 23(Suppl 8):64-8.
47. Glover D, Glick JH, Weiler C, Fox K, Turrisi A, Kligerman MM. Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1986; 12:1509-12.
48. Glover D, Glick JH, Weiler C, Hurowitz S, Kligerman MM. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4:584-8.
49. Glover D, Click JH, Weiler C, Fox K, Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5:574-8.
50. MollmanJE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy: risk factors, prognosis, and protection by WR-2721. Cancer 1988; 61:2192-5.
51. Capizzi RL, Oster W. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Eur J Cancer 1995; 31A(Suppl 1):S8-13.
52. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996; 14:1913-21.
53. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80:1134-40.
54. Betticher DC, Anderson H, Ranson M, Meely K, Oster W, Thatcher N. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Br J Cancer 1995; 72:1551-5.
55. Wagner W, Prott F-J, Schönekäs KG. Amifostine: a radioprotector in locally advanced head and neck tumors. Oncol Rep 1998; 5:1255-7.
56. Büntzel J, Schuth J, Küttner K, Glatzel M. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 1998; 6:155-60.
57. Poplin EA, Lo Russo P, Lokich JJ, et al. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1994; 33:415-9.
58. Mohr P, Makki A, Breitbart E, Schadendorf D. Combined treatment of stage IV melanoma patients with amifostine and fotemustine - a pilot study. Melanoma Res 1998; 8:166-9.
59. Adamson PC, Balis FM, Belasco JE, et al. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 1995; 55: 4069-72.
60. Nagy B, Grdina DJ. Protective effects of 2-[(aminopropyl)amino] ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells. Int J Radiat Oncol Biol Phys 1986; 12:1475-8.
61. Milas L, Murray D, Brock WA, Meyn RE. Radioprotectors in tumor radiotherapy: factors and settings determining therapeutic ratio. Pharmacol Ther 1988; 39:179-87.
62. Grdina DJ, Shigematsu N, Dale P, Newton GL, Aguilera JA, Fahey RC. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 1995; 16:767-74.
63. Kataoka Y, Perrin J, Hunter N, Milas L, Grdina DJ. Antimutagenic effects of amifostine: clinical implications. Semin Oncol 1996; 23(Suppl 8):53-7.
64. O'Brien W. Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Ann Oncol 1996; 7(Suppl 6):S27.
65. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998; 83:71-86.
66. Vallespi T, Imbert M, Mecucci C, Preudhomme C, Fenaux P. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 1998; 83:258-75.
67. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998, 83:358-68.
68. Cazzola M, Anderson JE, Ganser A, Hellström-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998, 83: 910-35.
69. Estey EH. Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica 1998; 83: 543-49.
70. List AF, Brasfield F, Heaton R, et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90:3364-9.
71. List AF. Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS? Leuk Res 1998; 22:S7-11.
72. Klimecki W, Heaton R, Glinsmann-Gibson B, List AF. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine-like effects [abstract]. Blood 1997, 90(Suppl 1):2317.
73. Bowen DT, Denzlinger C, Brugger W, et al. Poor response rate to a continuous schedule of amifostine therapy for low/intermediate risk myelodysplastic patients. Br J Haematol 1998; 103:785-7.
74. Grossi A, Fabbri A, Santini V, et al. Amifostine alone and in combination with low-dose ara-c in the treatment of myelodysplastic syndromes [abstract]. Leuk Res 1999; 23(Suppl 1):202.
75. List A. Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes. Forum Trends in Experimental and Clinical Medicine 1999; 9: 35-45.
76. Schuchter LM. Guidelines for the administration of amifostine. Semin Oncol 1996; 23(Suppl 8):40-3.
77. Buresh CM, Baker KS. Fever and rash after amifostine therapy. J Pediatr Hematol Oncol 1998; 20:361-3.
78. Bukowski RM. Amifostine (Ethyol®): dosing, administration and patient management guidelines. Eur J Cancer 1996; 32A(Suppl 4):S46-9.
79. Capizzi RL. Clinical status and optimal use of amifostine. Oncology 1999; 13:47-59.